264 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
Rank Status Study
21 Approved for marketing Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Intervention: Drug: cabozantinib
22 No longer available Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program
Conditions: Hepatitis B;   Chronic Disease
Intervention: Drug: Entecavir
23 Approved for marketing Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization
Condition: Autologous Stem Cell Transplant
Intervention: Drug: AMD3100 + G-CSF
24 No longer available Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment
Condition: Valuable Suggestions to Improve Health Care Quality Transparent and Accessible Medical Care
Intervention: Behavioral: questionnaire
25 Unknown  Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Paclitaxel Cisplatin
26 Available Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Idelalisib;   Drug: Rituximab
27 No longer available Compassionate Use of the Becker Expander/Breast Implant
Condition: Breast Reconstruction
Interventions: Device: Becker 50 Expander/Breast implant;   Device: Becker 25 Expander/Breast implant
28 Available To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia
Condition: Arrhythmia
Intervention: Other: MCG
29 Available INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis (PMF);   Post Polycythemia Myelofibrosis (PPV MF);   Post-essential Thrombocythemia Myelofibrosis (PET-MF);   Myelofibrosis;   Post Polycythemia Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Intervention: Drug: INC424
30 Available Compassionate Use of Stiripentol in Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: Stiripentol
31 Available The Effect of Adding Magnesium Sulfate to Standard Epidural and Interscalene Block in Treatment of Patients With Chronic Pain
Condition: Pain
Intervention: Drug: Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain
32 No longer available Erwinase Master Treatment Protocol
Conditions: Leukemia, Acute Lymphoblastic;   Acute Lymphoid Leukemia
Intervention: Drug: Erwinia L-asparaginase
33 Temporarily not available Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: R(+) pramipexole dihydrochloride monohydrate
34 No longer available A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
Condition: HIV
Intervention: Drug: Maraviroc
35 Available A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome
Conditions: Diabetes;   CVD
Intervention: Drug: Rosuvastatin,SFC fenofibrate
36 Available Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
Condition: Infection Due to Resistant Organism
Intervention: Drug: Arbekacin Sulfate
37 Available Use of Eylea for the Treatment of an Optic Nerve Hemangioma
Condition: Retinal Hemangioma
Intervention: Drug: Aflibercept
38 Available Effects of High-intensity Interval Training in Patients in Hemodialysis
Conditions: Chronic Renal Disease;   Hemodialysis
Intervention: Other: exercise
39 No longer available Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: AMN107
40 Unknown  Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 diaminopyridine

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years